Conference Coverage

Practice-Changing Advances in Early HER2-Positive Breast Cancer: ASCO 2026 and FDA Approvals Establish Trastuzumab Deruxtecan as a New Standard

TLX591-Tx in Combination With Standard-of-Care in Metastatic Castration-Resistant Prostate Cancer: Results From Part 1 of the Phase 3 ProstACT Global Study

Advances, Sequencing Challenges, and Real-World Integration of ADCs in Breast Cancer: Insights from ASCO 2026

This year, the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting will feature a breadth of new data on emerging antibody-drug conjugates (ADCs) and T-cell engagers (TCEs), particularly across solid tumors and hematologic malignancies. This article synthesizes pivotal findings from AbbVie’s next-generation ADC and TCE platforms—including SEZ6-, PSMA/STEAP1-, c-Met-, and FRα-targeted ADCs—alongside immune checkpoint inhibitor combinations and real-world evidence.

AACR 2026: Emerging Antibody-Drug Conjugates for the Treatment of Solid Tumors (Part 1)

The field of antibody-drug conjugates (ADCs) and bispecific antibody-drug conjugates (bsADCs) is rapidly expanding, offering new hope for the treatment of a range of solid tumors with high unmet medical need. Recent abstracts from the annual meeting of the American Association for Cancer Research (AACR), held April 17 - 22, 2026, in San Diego, CA, highlight several promising technological and therapeutic advances with Biocytogen’s RenLite® transgenic mouse platform and proprietary linker/payload technologies at the forefront.

NEOK002 (previously known as ABL209) is a novel, bispecific ADC designed to simultaneously target two key cancer antigens—Epidermal Growth Factor Receptor (EGFR), a key oncogenic driver in multiple tumor types, and Mucin-1 (MUC1), a tumor-associated antigen characterized by aberrant glycosylation and overexpression.

Recent advances in antibody-drug conjugate (ADC) technology have enabled the development of highly potent, tumor-targeted therapeutics with improved efficacy and safety. Sutro Biopharma, leveraging its site-specific and cell-free protein synthesis platform, has reported robust preclinical data for its pipeline of next-generation ADCs at the annual meeting of the American Association for Cancer Research (AACR), held April 17 - 22, 2026.

Recent Advances in the Clinical Development of First- and Best-in-Class Antibody-Drug Conjugates: Pipeline Update from Adcendo

ZW191: A Next-Generation FRα-Targeted ADC Demonstrates Promising Efficacy and Safety in Advanced Solid Tumors